Viridian taking on Amgen in TED market

A second positive Phase III readout in just three months has Viridian’s veligrotug poised to challenge Amgen’s Tepezza in the thyroid eye disease market.

Viridian Therapeutics Inc. (NASDAQ:VRDN) announced Monday that the Phase III THRIVE-2 trial of veligrotug met the primary and secondary endpoints in the chronic thryoid eye disease (TED) setting. On the primary endpoint of proptosis responder rate (PRR), Viridian said 56% of patients treated with the anti-IGF1R mAb met the responder criteria vs. just 8% for placebo — a 48% placebo-adjusted PRR at week 15. ...